نشریات بند

جاری کہانی · 1 رپورٹ

FDA approval and access to daraxonrasib

پہلی بار نشر ہوا تازہ ترین نشریہ

جاری ہےاگلی جانچ : Updates on availability, pricing, insurance coverage and Medicare patients’ access to daraxonrasib.

صورتِ حال

The FDA approved daraxonrasib (Rasonque), a once-daily pill for pancreatic cancer, after a trial found median survival was 13.2 months, compared with 6.7 months. Its nearly $40,000 monthly list price leaves many Medicare patients without access to the copay card; the reports give no further access or pricing developments.

خبر ٹریکردن 1

1 رپورٹ9 ذرائع ابلاغ11 ماخذ1 ویڈیو

  • ابھی کوئی تاریخ والا واقعہ نہیں
    1. اپ ڈیٹ 1FDA Approves First RAS-Targeted Pill for Metastatic Pancreatic Cancer

    خبر اب تک

    1. اپ ڈیٹ 1

      FDA Approves First RAS-Targeted Pill for Metastatic Pancreatic Cancer

      Daraxonrasib targets the mutation behind more than 90% of cases and nearly doubled life expectancy in its pivotal trial, a landmark for a cancer with 13% five-year survival.

      اس رپورٹ کے بعد بھی حل طلب

      • No verified price, coverage terms, or out-of-pocket burden in these excerpts.
      • No verified exact survival months, side-effect rates, or full label details in these excerpts.

    تاریخچہ

    1. شروع ہوئی1 رپورٹ

    کون شامل ہے

    مقامات

    • Dana-Farber Cancer Institute450 Brookline Ave, Boston, MA 02215, USA1 رپورٹ
    • United StatesUnited States1 رپورٹ

    اس خبر پر ہم نے جتنے ذرائع ابلاغ پڑھے

    11 ماخذ9 ذرائع ابلاغ1 ویڈیو